Transcription factor AP2C controls multiple pathways of estrogen signaling, a U.S. study revealed. Researchers also found that silencing the gene restricted tumor growth in mice and stopped the expression of the GPR30 estrogen receptor. They hope the finding may lead to development of drugs for hormone-responsive breast cancers.

Full Story:

Related Summaries